Aryx Therapeutics Operating Income

Aryx Therapeutics posts a operating income of $-17M as of September 2010. That compares with $-38M in the prior-year period — up 56.5% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Aryx Therapeutics's operating income was $-38M. The latest reading is $-17M — a 56.5% year-over-year increase (period ending September 2010). Use the history and growth charts on this page for a longer lookback.

Operating Income is one piece of Aryx Therapeutics's financial statement story. At $-17M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for ARYX's operating income usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Aryx Therapeutics's other metric pages and overview cover the third.

Judging Aryx Therapeutics against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in operating income easier to interpret. Start with $-17M here, then scan peer and history charts to see if the gap is persistent.